Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deoxycholic acid
Drug ID BADD_D00609
Description Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures.
Indications and Usage For improvement in appearance of moderate to severe fullness associated with submental fat in adults.
Marketing Status approved
ATC Code D11AX24
DrugBank ID DB03619
KEGG ID D10781
MeSH ID D003840
PubChem ID 222528
TTD Drug ID Not Available
NDC Product Code 61168-101; 66039-937; 50384-0151
UNII 005990WHZZ
Synonyms Deoxycholic Acid | Desoxycholic Acid | Dihydroxycholanoic Acid | Choleic Acid | Deoxycholate | Deoxycholic Acid, 12beta-Isomer | 12beta-Isomer Deoxycholic Acid | Deoxycholic Acid, 12beta Isomer | Deoxycholic Acid, 3beta-Isomer | 3beta-Isomer Deoxycholic Acid | Deoxycholic Acid, 3beta Isomer | Deoxycholic Acid, 5alpha-Isomer | 5alpha-Isomer Deoxycholic Acid | Deoxycholic Acid, 5alpha Isomer | Deoxycholic Acid, Magnesium (2:1) Salt | Deoxycholic Acid, Monoammonium Salt | Deoxycholic Acid, Monopotassium Salt | Deoxycholic Acid, Monosodium Salt | Sodium Deoxycholate | Deoxycholate, Sodium | Deoxycholic Acid, Sodium Salt, 12beta-Isomer | Lagodeoxycholic Acid | Kybella | Deoxycholic Acid, Disodium Salt
Chemical Information
Molecular Formula C24H40O4
CAS Registry Number 83-44-3
SMILES CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alopecia23.02.02.0010.005426%
Blister23.03.01.001; 12.01.06.0020.001596%Not Available
Condition aggravated08.01.03.0040.006419%Not Available
Dermatitis23.03.04.0020.000603%Not Available
Discomfort08.01.08.0030.000603%Not Available
Drug ineffective08.06.01.0060.026830%Not Available
Dysarthria17.02.08.001; 19.19.03.0010.000390%
Dyskinesia17.01.02.0060.000603%
Dysphagia07.01.06.0030.003405%
Ear pain04.03.01.0030.000603%
Erythema23.03.06.0010.003493%Not Available
Eye swelling06.08.03.0030.000904%Not Available
Facial pain08.01.08.0120.001507%
Facial paralysis17.04.03.0080.001596%Not Available
Fat tissue increased08.01.03.0090.003015%Not Available
Feeling abnormal08.01.09.0140.002199%Not Available
Feeling cold08.01.09.0080.000603%Not Available
Glossodynia07.14.02.0010.000603%Not Available
Haematoma24.07.01.0010.000904%
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hyperplasia08.03.04.0080.000390%Not Available
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.0230.011544%Not Available
Injection site bruising24.07.06.017; 12.07.03.042; 23.03.11.015; 08.02.03.0420.004575%Not Available
Injection site cyst16.02.02.011; 12.07.03.044; 08.02.03.0440.000603%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.006473%Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.0050.000993%Not Available
Injection site hypersensitivity10.01.03.017; 08.02.03.006; 12.07.03.0060.000692%Not Available
Injection site hypertrophy12.07.03.026; 08.02.03.0260.000603%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages